Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

In this institution-based randomized trial, oral betamethasone mini-pulse therapy for alopecia areata showed a faster therapeutic response compared to oral tofacitinib, as measured by trichoscopic changes and achievement of 50% hair regrowth.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

This review discusses the challenges and opportunities in targeting the hedgehog pathway for aggressive cancers, emphasizing the complexities of treatment resistance, immune response, and the potential of combining immune checkpoint inhibitors with hedgehog pathway inhibitors, but reports no new clinical results.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This review highlights concerns about the potential negative effects of chemicals in cosmetic products on the health of pregnant women, fetuses, and newborns, stressing the need for more research.

Hair shaft changes may be linked to CCCA, but their role is unclear.